Code availability
NB
Requests for access to code should be made to the corresponding author and will be reviewed by the Peninsula Research Bank Steering Committee. Access to code through the Peninsula Research Bank will be granted for requests with scientifically valid questions by academic teams with the necessary skills appropriate for the research. Code will be released by the lead statistician.Study design for the TriMaster three-treatment, three-period crossover trial of pioglitazone, sitagliptin, and canagliflozin. Six sequences represent the 6 possible treatment orders for pioglitazone (P), canagliflozin (C) and sitagliptin (S). No washout between treatment periods (see Flow diagram showing participant flow through the study, with full breakdown of numbers on each drug at each stage and exclusions. P=pioglitazone, S=sitagliptin, C=canagliflozin.a) Mean HbA1c b) mean number of side effects and c) weight at end of treatment period for each of the three therapies (pioglitazone in blue, sitagliptin in yellow, canagliflozin in red) split by the participants’ preferred drug on final ranking (shown by light background - pioglitazone in light blue, sitagliptin light yellow, canagliflozin in pink). Error bars represent 95% confidence intervals.On-treatment characteristics of 457 participants who tried all 3 drugs. Data presented as mean and 95% confidence intervals or n(%); P values determined using mixed effects models adjusting for period.HbA1c only valid if on therapy for at least 12 weeks and 80% adherence based on pill count;P value for Yes/Maybe v No across the three drugsNumber of individuals achieving specific optimal results by drug. For each drug, the number (and % [95% CI]) of participants that have the lowest HbA1c, side effects, and weight on that drug. NB participants can have the lowest value on more than one drug so row totals add up to >100%.Only presented for participants where a preferred drug was chosen.7 participants had no valid HbA1cs for any of the three drugsPatient’s preference of drug before and after being fed back information on the HbA1c and weight at the end of the 3 treatment courses. Data presented as number and percentage preferred drug [95% confidence intervals] and mean rank. Ranking of drugs is 1 for preferred, 3 for least preferred, so lower mean rank represents higher preference for the drug.P values calculated for those who expressed a preference, based on chi-squared test compared with equal preference.